3.20 USD
▼-0.06-1.69%
盘后 3.50 0.00%
2026-11-20
市值
$333.54M
市盈率
—
EPS
-0.59
股息率
—
52 周区间
1.30 – 6.83
成交量
171.41K
Beta
1.19
目标价
8.80
52W 低 1.3052W 高 6.83
价格走势
公司简介
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCel...